{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:33Z","timestamp":1787019573995,"version":"build-2736575974"},"reference-count":41,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>RAS pathway (RASp) mutations induce proliferative features, and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASp mutations remain unexplored. To characterize the landscape, architecture, and implications of unique RASp mutations in CMML, we evaluated a cohort of 814 patients with CMML. We identified 461 RASp mutations among 342 patients (42%). N\/KRAS and CBL mutations were the most common, frequently involved the P-loop or RING domains, respectively, and frequently appeared as dominant events (63% and 65%, respectively). BRAF, NF1, and PTPN11 mutations spanned throughout the gene structure, and frequently appeared as subclonal events (75%, 64%, and 59%, respectively). CBL mutations frequently occurred in codominance with SRSF2 and multihit TET2, and were enriched for KIT mutations. PTPN11 mutations more frequently co-occurred with SETBP1 and DNMT3A mutations, and were infrequently codominant with TET2 or ASXL1. RASp mutations predicted for shorter overall survival (hazard ratio [HR], 1.55; 95% confidence interval [CI], 1.15-2.07; P = .0075) and leukemia-free survival (LFS; HR, 1.67; 95% CI, 1.26-2.20; P = .0011), influenced outcomes of myelodysplastic and TET2 mutant CMML, and cooperated with IDH2 and RUNX1 mutations to induce shorter LFS. These data set the bases for refined genomic classifications of CMML, and underscore the need to develop RAS-directed therapies for patients with CMML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016529","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:05:25Z","timestamp":1752260725000},"page":"5105-5117","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia"],"prefix":"10.1182","volume":"9","author":[{"given":"Guillermo","family":"Montalban-Bravo","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-0533","authenticated-orcid":false,"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuya","family":"Natu","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurney","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bazinet","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1221-8854","authenticated-orcid":false,"given":"Clifford","family":"Csizmar","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso-Ramos","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"12","key":"2025101411213807500_bib1","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2025101411213807500_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2025101411213807500_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025101411213807500_bib4","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2025101411213807500_bib5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2025101411213807500_bib6","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2025101411213807500_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2018024216","article-title":"Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia","volume":"3","author":"Awada","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2025101411213807500_bib8","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/leu.2017.164","article-title":"Genomic determinants of chronic myelomonocytic leukemia","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2025101411213807500_bib9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41375-024-02190-1","article-title":"Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia","volume":"38","author":"Montalban-Bravo","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2025101411213807500_bib10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025101411213807500_bib11","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"2025101411213807500_bib12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41375-020-0889-7","article-title":"Landscape of RAS pathway mutations in patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients","volume":"35","author":"Buradkar","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2025101411213807500_bib13","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025101411213807500_bib14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","article-title":"Activity of venetoclax-based therapy in chronic myelomonocytic leukemia","volume":"35","author":"Montalban-Bravo","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2025101411213807500_bib15","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.xcrm.2024.101585","article-title":"Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia","volume":"5","author":"Montalban-Bravo","year":"2024","journal-title":"Cell Rep Med"},{"issue":"4","key":"2025101411213807500_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.19060","article-title":"Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia","volume":"203","author":"Montalban-Bravo","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2025101411213807500_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jtho.2025.01.006","article-title":"A single-arm, phase 2 study of sotorasib plus carboplatin and pemetrexed in patients with advanced non-squamous NSCLC with KRAS G12C mutation (WJOG14821L, SCARLET)","volume":"20","author":"Akamatsu","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2025101411213807500_bib18","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"2025101411213807500_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"2025101411213807500_bib20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025101411213807500_bib21","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1038\/s41375-022-01727-6","article-title":"Srsf2P95H\/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice","volume":"36","author":"Xu","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"2025101411213807500_bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025101411213807500_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353118","article-title":"Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition","volume":"141","author":"Simons","year":"2013","journal-title":"Cytogenet Genome Res"},{"issue":"5","key":"2025101411213807500_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"2025101411213807500_bib25","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41375-023-01887-z","article-title":"Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis","volume":"37","author":"Lasho","year":"2023","journal-title":"Leukemia"},{"issue":"7834","key":"2025101411213807500_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"issue":"22","key":"2025101411213807500_bib27","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2025101411213807500_bib28","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1038\/s41375-022-01733-8","article-title":"Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia","volume":"36","author":"Garcia-Gisbert","year":"2022","journal-title":"Leukemia"},{"key":"2025101411213807500_bib29","doi-asserted-by":"crossref","first-page":"107391","DOI":"10.1016\/j.leukres.2023.107391","article-title":"TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia","volume":"134","author":"Gurney","year":"2023","journal-title":"Leuk Res"},{"issue":"24","key":"2025101411213807500_bib30","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"282","key":"2025101411213807500_bib31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Journal Am Stat Assoc"},{"key":"2025101411213807500_bib32","unstructured":"The R Core Team\n          . R: a language and environment for statistical computing. Accessed 21 July 2025. https:\/\/www.R-project.org."},{"key":"2025101411213807500_bib33","volume-title":"The jamovi project","year":"2021"},{"issue":"10","key":"2025101411213807500_bib34","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3324\/haematol.2024.285410","article-title":"ASXL1\/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia","volume":"109","author":"Csizmar","year":"2024","journal-title":"Haematologica"},{"issue":"19","key":"2025101411213807500_bib35","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025101411213807500_bib36","doi-asserted-by":"crossref","first-page":"101933","DOI":"10.1016\/j.xcrm.2025.101933","article-title":"An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia","volume":"6","author":"Gurashi","year":"2025","journal-title":"Cell Rep Med"},{"issue":"6","key":"2025101411213807500_bib37","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2643-3230.BCD-21-0217","article-title":"Progenitor hierarchy of chronic myelomonocytic leukemia identifies inflammatory monocytic-biased trajectory linked to worse outcomes","volume":"3","author":"Ferrall-Fairbanks","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"8041","key":"2025101411213807500_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"12","key":"2025101411213807500_bib39","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1172\/JCI121366","article-title":"Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy","volume":"128","author":"Zhang","year":"2018","journal-title":"J Clin Invest"},{"issue":"1","key":"2025101411213807500_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/ejh.13768","article-title":"Multistep pathogenesis of chronic myelomonocytic leukemia in patients","volume":"109","author":"Geissler","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025101411213807500_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ccell.2017.11.012","article-title":"Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity","volume":"33","author":"Kunimoto","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2025016529\/2416479\/blooda_adv-2025-016529-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2025016529\/2416479\/blooda_adv-2025-016529-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:22:21Z","timestamp":1760455341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/5105\/546155\/Landscape-and-clinicopathologic-features-of-RAS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":41,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016529","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,10,14]]}}}